 |
VIDEO RELEASE -- Galena Biopharma Reports First Quarter 2013 Financial Results May 9, 2013 |
24.0 KB |
|||
|
Lead product, NeuVax™ (nelipepimut-S), reached global site enrollment milestone for Phase 3 PRESENT trial; and commenced enrolling a Phase 2b in combination with Herceptin®.Completed Abstral® product acquisition in the U.S., with launch targeted in the 4th Quarter of 2013.Operating loss from continuing operations for the quarter end... |
|||||
|
Galena Biopharma Poster Presentation at the American Pain Society 32nd Annual Scientific Meeting May 9, 2013 |
12.0 KB |
|||
|
Abstral® (fentanyl) Sublingual Tablets are an important new treatment option for inadequately controlled breakthrough cancer pain (BTcP) which impacts the majority of cancer patients at some point in their care. Abstral, the first and only sublingual fentanyl tablet for BTcP, TIRF REMS serves as model program. LAKE OSWEGO, Ore., May 9... |
|||||
|
William L. Ashton Joins Galena Biopharma's Board of Directors May 1, 2013 |
10.8 KB |
|||
|
LAKE OSWEGO, Ore., May 1, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the addition of William L. Ashton to the Company's Board of Directors. Mr. Ashton is a senior executive ... |
|||||
|
Galena Biopharma to Present at the 12th Annual Needham Healthcare Conference Apr 24, 2013 |
8.7 KB |
|||
|
LAKE OSWEGO, Ore., April 24, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer, will present a corporate update at the 12... |
|||||
|
Galena Biopharma to Present at the 2013 BIO International Convention Apr 16, 2013 |
8.3 KB |
|||
|
LAKE OSWEGO, Ore., April 16, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark W. Schwartz, Ph.D., Executive Vice President and Chief Operating Officer, will present a corpor... |
|||||
|
Galena Biopharma to Present at the 20th Annual Future Leaders in the Biotech Industry Conference Mar 29, 2013 |
8.7 KB |
|||
|
LAKE OSWEGO, Ore., March 29, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer, will present a corporate update at the 20... |
|||||
|
Galena Biopharma Acquires Abstral(R) (fentanyl) Sublingual Tablets in U.S., a Novel, Best-in-Class Treatment Approved for Breakthrough Cancer Pain Mar 18, 2013 |
16.4 KB |
|||
|
Abstral® was approved in the U.S. in 2011 and is the first and only fentanyl sublingual tablet for the management of breakthrough cancer pain in opioid tolerant patients. Abstral® product launch targeted in the 4th Quarter of 2013. To fund the acquisition and product launch, Galena plans to enter into a non-dilutive debt financi... |
|||||
|
Galena Biopharma Receives 2013 Global Frost & Sullivan Award for New Product Innovation for NeuVax(TM) Mar 14, 2013 |
11.1 KB |
|||
|
LAKE OSWEGO, Ore., March 14, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced that independent research firm, Frost & Sullivan, has recognized Galena Biopharma with the 2013 Global Frost & ... |
|||||
|
Galena Biopharma Reports Year-End 2012 Financial Results Mar 12, 2013 |
27.8 KB |
|||
|
Operating loss from continuing operations for the year ended December 31, 2012 was $21.2 million, including $1.8 million in stock-based compensation.NeuVax™ (nelipepimut-S or E75) Phase 3 PRESENT trial being conducted under a Special Protocol Assessment (SPA) is currently enrolling in over 100 clinical sites worldwide.Phase 2b clinical trial ... |
|||||
|
Galena Biopharma to Present at the 25th Annual ROTH Conference Mar 11, 2013 |
9.0 KB |
|||
|
LAKE OSWEGO, Ore., March 11, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer, will present a corporate update at the... |
|||||
|
Galena Biopharma to Present at the 7th Annual Bio-Europe International Partnering Conference Mar 4, 2013 |
8.8 KB |
|||
|
LAKE OSWEGO, Ore., March 4, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced that Mark W. Schwartz, Ph.D., Executive Vice President and Chief Executive Officer will present a cor... |
|||||
|
Galena Biopharma to Present at the 15th Annual Bio CEO & Investor Conference Feb 5, 2013 |
9.1 KB |
|||
|
LAKE OSWEGO, Ore., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer, will present a corporate update at the... |
|||||
|
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants Dec 18, 2012 |
13.2 KB |
|||
|
LAKE OSWEGO, Ore., Dec. 18, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE) announced today the pricing of an underwritten public offering of 15,156,250 units at a public offering price of $1.60 per unit, or total gross proceeds of $24.25 million. Each unit consists of one share of common stock, and a warrant to purchase 0.5 share of common... |
|||||
|
Galena Biopharma Announces Public Offering of Common Stock and Warrants Dec 17, 2012 |
13.0 KB |
|||
|
LAKE OSWEGO, Ore., Dec. 17, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE) announced today that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when th... |
|||||
|
Galena Biopharma Presents Final Landmark 60-Month Results From NeuVax(TM) Phase 1/2 Trials at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium Dec 7, 2012 |
17.7 KB |
|||
|
The combined SN-33 (Node Positive) and SN-34 (Node Negative) Intent-to-treat (ITT) population continued to demonstrate an excellent safety and efficacy profile.Phase 2 HER2 IHC 1+/2+ patients from SN-33 established the Phase 3 patient population. After establishing statistical significance at the 36-month Landmark Analysis, or the same endpoint as ... |
|||||
|
Galena Biopharma and Leica Biosystems Announce Partnership to Develop Companion Diagnostic for HER2 Screening in Women With Breast Cancer Dec 6, 2012 |
15.5 KB |
|||
|
Leica Biosystems will develop a fully automated HER2 diagnostic to support identification of appropriate HER2 negative (IHC 1+/2+) patients for NeuVax™ (nelipepimut-S or E75)Galena strengthens its NeuVax personalized medicine and regulatory pathway with companion diagnostic development LAKE OSWEGO, Ore. and NEWCASTLE-UPON-TYNE, United Ki... |
|||||
|
Galena Biopharma to Present at the Oppenheimer 23rd Annual Healthcare Conference Dec 5, 2012 |
9.1 KB |
|||
|
LAKE OSWEGO, Ore., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and CEO, will present a corporate overview at the Oppenheim... |
|||||
|
Galena Biopharma Announces Signature of Commercialization Partnership With Teva for Israel Dec 4, 2012 |
13.4 KB |
|||
|
Partnership includes future commercialization of NeuVax™ in Israel and financial support Key clinical sites approved and established in Israel for PRESENT Phase 3 trial LAKE OSWEGO, Ore., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology ... |
|||||
|
Galena Biopharma Announces NeuVax(TM) Poster Presentations at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium Nov 29, 2012 |
12.4 KB |
|||
|
LAKE OSWEGO, Ore., Nov. 29, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced two presentations at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium. The event will be... |
|||||
|
Galena Biopharma to Present at the Piper Jaffray 24th Annual Healthcare Conference Nov 20, 2012 |
8.8 KB |
|||
|
LAKE OSWEGO, Ore., Nov. 20, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and CEO, will present a corporate overview at the Piper Ja... |
|||||
|
|||||
Contact:
info@GalenaBiopharma.com